Profile data is unavailable for this security.
About the company
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
- Revenue in USD (TTM)493.67m
- Net income in USD-104.69m
- Incorporated2002
- Employees517.00
- LocationAmicus Therapeutics Inc47 Hulfish St.PRINCETON 08542United StatesUSA
- Phone+1 (609) 662-2000
- Fax+1 (609) 662-2001
- Websitehttps://www.amicusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | 0.00 | -146.66m | 2.51bn | 91.00 | -- | 3.32 | -- | -- | -2.67 | -2.67 | 0.00 | 12.91 | 0.00 | -- | -- | 0.00 | -24.39 | -- | -25.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 90.86m | -410.00m | 2.51bn | 557.00 | -- | 3.25 | -- | 27.64 | -1.50 | -1.50 | 0.3273 | 2.54 | 0.0986 | 3.24 | -- | 163,120.30 | -44.48 | -51.47 | -50.17 | -57.56 | 14.75 | -- | -451.25 | -137,873.80 | 3.90 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Belite Bio Inc (ADR) | 0.00 | -33.03m | 2.52bn | 20.00 | -- | 22.69 | -- | -- | -1.11 | -1.11 | 0.00 | 3.63 | 0.00 | -- | -- | 0.00 | -38.10 | -- | -38.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 929.24m | 128.51m | 2.69bn | 620.00 | 20.87 | 4.66 | 19.12 | 2.90 | 0.7753 | 0.7753 | 5.60 | 3.47 | 1.15 | 1.91 | 9.73 | 1,556,509.00 | 15.97 | -27.50 | 24.34 | -32.73 | 91.61 | 95.62 | 13.83 | -38.35 | 2.11 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| SpringWorks Therapeutics Inc | 135.49m | -275.16m | 2.70bn | 305.00 | -- | 5.08 | -- | 19.90 | -3.89 | -3.89 | 1.89 | 7.15 | 0.2517 | -- | -- | 444,219.70 | -51.12 | -36.97 | -57.59 | -39.49 | 94.52 | -- | -203.09 | -2,176.46 | 6.02 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Kymera Therapeutics Inc | 87.56m | -167.47m | 2.82bn | 184.00 | -- | 3.16 | -- | 32.18 | -2.33 | -2.33 | 1.26 | 13.79 | 0.1103 | -- | 34.37 | 468,251.30 | -21.10 | -23.03 | -22.98 | -27.64 | -- | -- | -191.26 | -207.82 | -- | -- | 0.0035 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Amicus Therapeutics, Inc. | 493.67m | -104.69m | 2.84bn | 517.00 | -- | 15.87 | -- | 5.75 | -0.3461 | -0.3461 | 1.63 | 0.5987 | 0.6367 | 0.5739 | 5.76 | 954,876.20 | -13.50 | -30.65 | -17.12 | -36.55 | 89.99 | 88.94 | -21.21 | -86.10 | 2.42 | 0.3214 | 0.6853 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Vera Therapeutics Inc | 0.00 | -134.38m | 2.98bn | 82.00 | -- | 8.95 | -- | -- | -2.60 | -2.60 | 0.00 | 5.25 | 0.00 | -- | -- | 0.00 | -49.39 | -- | -54.50 | -- | -- | -- | -- | -- | -- | -- | 0.1487 | -- | -- | -- | -7.79 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -213.39m | 3.02bn | 251.00 | -- | 3.78 | -- | -- | -2.81 | -2.81 | 0.00 | 10.53 | 0.00 | -- | -- | 0.00 | -28.32 | -20.71 | -29.38 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Veracyte Inc | 425.33m | -9.27m | 3.02bn | 815.00 | -- | 2.57 | 211.42 | 7.10 | -0.1445 | -0.1445 | 5.61 | 15.18 | 0.3545 | 7.40 | 9.66 | 521,878.50 | -0.7723 | -6.33 | -0.8157 | -6.69 | 68.45 | 67.10 | -2.18 | -20.99 | 4.79 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Dyne Therapeutics Inc | 0.00 | -294.51m | 3.03bn | 173.00 | -- | 4.29 | -- | -- | -3.56 | -3.56 | 0.00 | 6.93 | 0.00 | -- | -- | 0.00 | -60.47 | -52.81 | -65.37 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Edgewise Therapeutics Inc | 0.00 | -124.29m | 3.03bn | 108.00 | -- | 6.18 | -- | -- | -1.49 | -1.49 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -30.22 | -- | -31.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.17bn | 383.00 | 4.52 | 1.95 | 4.32 | 96.36 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Data as of Nov 21 2024. Currency figures normalised to Amicus Therapeutics Inc's reporting currency: US Dollar USD
60.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Sep 2024 | 28.06m | 9.46% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 28.00m | 9.44% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 23.74m | 8.00% |
| Avoro Capital Advisor LLCas of 30 Sep 2024 | 23.18m | 7.81% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 22.17m | 7.47% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 15.64m | 5.27% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 10.97m | 3.70% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 10.81m | 3.65% |
| Redmile Group LLCas of 30 Sep 2024 | 8.25m | 2.78% |
| Palo Alto Investors LPas of 30 Sep 2024 | 8.15m | 2.75% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
